<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112926</url>
  </required_header>
  <id_info>
    <org_study_id>20210848</org_study_id>
    <nct_id>NCT05112926</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Embosphere Microspheres for Embolization of the Geniculate Artery for the Treatment of Pain With Known Moderate to Severe Knee Osteoarthritis</brief_title>
  <official_title>Prospective, Single Arm Investigation to Assess Effectiveness and Safety of Embosphere Microspheres for Embolization of the Geniculate Artery for the Treatment of Pain With Known Moderate to Severe Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shivank Bhatia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the effectiveness and safety of a permanent&#xD;
      embolic (Embosphere Microspheres) for embolization of the geniculate artery for the treatment&#xD;
      of moderate to severe knee osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in knee pain as assessed by the WOMAC</measure>
    <time_frame>Baseline, 24 Weeks (Post Embolization Surgery)</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain index assesses participants' pain on a scale ranging from 0 (none) to 4 (extreme). The pain subscale consists of 5 items and total scores can range from 0-20, with larger scores indicating greater pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment related adverse events</measure>
    <time_frame>Up to 4 weeks (Post Embolization Surgery)</time_frame>
    <description>Procedure-related and target knee osteoarthritis-related adverse events as assessed by treating physician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in knee pain as assessed by VAS</measure>
    <time_frame>Baseline, up to 52 weeks (Post Embolization Surgery)</time_frame>
    <description>Visual Analog Scale (VAS) has a total score ranging from 0-10 with the higher score indicating greater pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in knee pain</measure>
    <time_frame>Baseline, up to 52 weeks (Post Embolization Surgery)</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain index assesses participants' pain on a scale ranging from 0 (none) to 4 (extreme). The pain subscale consists of 5 items and total scores can range from 0-20, with larger scores indicating greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 52 weeks (Post Embolization Surgery)</time_frame>
    <description>Procedure-related and target knee osteoarthritis-related adverse events as assessed by treating physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WORMS Score for Synovitis</measure>
    <time_frame>Baseline, up to 52 weeks (Post Embolization Surgery)</time_frame>
    <description>Whole-Organ Magnetic Resonance Imaging Score (WORMS) has a score ranging from zero representing no knee problems and 332 representing knee problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kellgren-Lawrence Grade</measure>
    <time_frame>Baseline, up to 52 weeks (Post Embolization Surgery)</time_frame>
    <description>As assessed by X-Ray. Radiograph imaging graded on scale 1 (no arthritis) to 4 (severe arthritis)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Embosphere Microspheres group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group who are receiving standard of care (SOC) embolization surgery for the treatment of moderate to severe knee osteoarthritis will receive the Embospheres Microspheres during scheduled SOC surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Embosphere Microspheres</intervention_name>
    <description>Embosphere Microspheres are 100-300Î¼m small, compressible, hydrophilic, biocompatible spheres made of acrylic polymer and porcine-derived gelatin used for embolization of geniculate artery.</description>
    <arm_group_label>Embosphere Microspheres group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has signed informed consent&#xD;
&#xD;
          -  Subject is age 40-80&#xD;
&#xD;
          -  Subject is able to have an MRI&#xD;
&#xD;
          -  Minimum of prior 12 weeks of failed response to conservative therapy for knee&#xD;
             osteoarthritis, which may include one or more of:&#xD;
&#xD;
             a) Oral or topical NSAIDS, opioid medications, intra-articular injection of&#xD;
             glucocorticoids or hyaluronic acid, physical therapy.&#xD;
&#xD;
          -  Localized tenderness in anterior knee area&#xD;
&#xD;
          -  Kellgren-Lawrence grade 1, 2, or 3 as assessed by weight-bearing knee radiographs&#xD;
&#xD;
          -  Synovitis present as assessed by WORMS&#xD;
&#xD;
          -  VAS &gt;50 mm&#xD;
&#xD;
          -  WOMAC score &gt;30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Local infection of the target knee(s)&#xD;
&#xD;
          -  Kellgren-Lawrence grade &gt;3&#xD;
&#xD;
          -  Osteonecrosis evident by MRI&#xD;
&#xD;
          -  Prior knee arthroplasty&#xD;
&#xD;
          -  Allergy to iodinated contrast agents that cannot be managed by prophylaxis&#xD;
&#xD;
          -  Hypersensitivity to gelatin products&#xD;
&#xD;
          -  Any known condition that limits catheter-based intervention or is a contraindication&#xD;
             to embolization&#xD;
&#xD;
          -  Active malignancy other than non-melanomatous skin cancer&#xD;
&#xD;
          -  Subject is pregnant, breastfeeding, or pre-menopausal and intending to become pregnant&#xD;
&#xD;
          -  Any other condition related to the subject's health and wellbeing deemed exclusionary&#xD;
             in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shivank Bhatia</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lia Quezada</last_name>
    <phone>305-243-2210</phone>
    <email>Lquezada@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lia Quezada</last_name>
      <phone>305-243-2210</phone>
      <email>Lquezada@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Shivank Bhatia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Shivank Bhatia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

